Genitourinary Syndrome of Menopause (GSM): Why It Gets Missed and How to Actually Manage It

What GSM Actually Is (and Why the Old Name "Vaginal Atrophy" Fell Short)

GSM is a collection of genital, sexual, and urinary symptoms caused by the loss of estrogen and other sex steroids. The term replaced "vaginal atrophy" in 2014 because atrophy implied a one-organ problem, when in fact the vulva, vagina, urethra, and bladder trigone are all estrogen-sensitive and all affected.

The Menopause Society's 2023 position statement describes GSM as "a chronic and progressive condition" that worsens the longer estrogen deprivation continues. Unlike vasomotor symptoms (hot flashes, night sweats) that often improve over time, GSM does not self-resolve. That distinction matters for how urgently you seek care.

The Physiology: What Estrogen Does for This Tissue

Estrogen maintains vaginal rugae (the folds that allow expansion), supports lactobacillus-dominant flora, keeps vaginal pH below 4.5, and sustains blood flow to the urethral mucosa. When estrogen drops, all of that changes. Vaginal pH rises to 6.0-7.5, creating conditions that favor pathogenic bacteria. The epithelium thins, loses glycogen, and stops self-lubricating adequately. The urethra, which shares embryologic origin with vaginal tissue, becomes shorter and more susceptible to irritation and infection.

Who Gets GSM

GSM is most strongly associated with menopause, but several other female life stages produce the same estrogen-depleted state:

• Postmenopausal women. Estrogen hits its lowest lifetime level. Up to 84% report at least one GSM symptom, though fewer than a quarter discuss it with a clinician.
• Perimenopause. Estrogen fluctuates erratically. Dryness and dyspareunia can appear years before the final menstrual period, which is why the diagnosis is often missed at this stage.
• Postpartum and lactating women. Prolactin suppresses ovarian estrogen. This is one of the most under-recognized causes of GSM in younger women. Symptoms typically resolve when lactation ends, but can be severe enough to require treatment in the interim.
• Women on GnRH agonists (leuprolide for endometriosis or fibroids) or aromatase inhibitors for breast cancer experience iatrogenic GSM within weeks of starting therapy.
• Women with premature ovarian insufficiency (POI). GSM can begin in the 20s or 30s for the roughly 1% of women who develop POI before age 40.

The Commonly Missed Diagnoses: Where GSM Gets Confused

GSM mimics, overlaps with, or is co-diagnosed alongside several other conditions. Getting this wrong means years of ineffective treatment.

Recurrent Urinary Tract Infections

This is the single most common misdiagnosis. Urinary urgency, frequency, dysuria, and nocturia are core GSM urinary symptoms. Women are often prescribed repeated antibiotic courses when cultures are negative or repeatedly show the same low-count contaminant.

A 2019 study in Menopause found that postmenopausal women with recurrent UTIs had significantly lower vaginal estrogen levels and higher vaginal pH compared to controls, and that vaginal estrogen therapy reduced UTI recurrence by roughly 50% over 12 months. If you are being treated for recurrent UTIs and cultures keep coming back negative or growing organisms at low counts, GSM belongs on the differential.

Vulvodynia and Chronic Pelvic Pain

Vulvodynia is unprovoked vulvar pain lasting more than three months. GSM can produce vulvar burning and pain that meets this definition, but the mechanism is different and so is the treatment. The two conditions can also coexist. A clinician who jumps to a vulvodynia diagnosis without checking estrogenic status misses a treatable hormonal cause. Examination findings help distinguish them: GSM shows visible tissue changes (pallor, loss of rugae, petechiae, urethral caruncle), whereas vulvodynia typically presents with normal-appearing tissue.

Lichen Sclerosus

Lichen sclerosus is an autoimmune dermatosis causing vulvar whitening, thinning, and architectural distortion. It is more common in postmenopausal women and shares the symptom of dyspareunia. GSM and lichen sclerosus can coexist in the same patient. ACOG Practice Bulletin No. 241 notes that a biopsy is the definitive test for lichen sclerosus when the clinical picture is unclear. Treating GSM alone when lichen sclerosus is present will produce incomplete relief.

Interstitial Cystitis / Bladder Pain Syndrome

Bladder pain, urgency, and frequency in a perimenopausal or postmenopausal woman can be referred to urology for an interstitial cystitis workup when GSM is the actual driver. The urethral mucosa depends on estrogen. When it atrophies, the sensory threshold drops and urgency becomes disproportionate to bladder fill. A trial of vaginal estrogen before invasive bladder testing is a reasonable clinical step.

Dyspareunia Attributed Solely to Relationship or Psychological Factors

Pain during sex in a woman over 45 is still too often attributed to reduced desire or relationship dynamics without a pelvic examination. GSM-related dyspareunia is mechanical: thin, dry tissue tears and bleeds at minimal friction. The REVIVE survey of 3,046 postmenopausal women found that 59% had not discussed vaginal symptoms with any clinician, and of those who had, many reported being told "it's just part of aging." That framing is both inaccurate and harmful.

How GSM Is Diagnosed

Diagnosis is clinical. You do not need blood tests or biopsies in most cases.

Symptom Assessment

The DIVA questionnaire (Day-to-Day Impact of Vaginal Aging) is a validated patient-reported outcome tool that covers four domains: sexual function, daily activities, emotional wellbeing, and hygiene and clothing concerns. Validation data published in Menopause support its use in both clinical practice and research.

Pelvic Examination Findings

A trained clinician looking for GSM expects to find some or all of:

• Loss of labial fullness and pubic hair thinning
• Pallor or erythema of the vaginal walls
• Loss of vaginal rugae (smooth, shiny appearance)
• Petechiae on the vaginal mucosa
• Urethral caruncle or urethral meatal prominence
• Reduced vaginal caliber and depth
• Vaginal pH above 5.0 (litmus paper test, performed before lubricant application)

Vaginal Maturation Index

A swab of the lateral vaginal wall, read as the ratio of parabasal to superficial cells, reflects estrogenic status. A high parabasal cell percentage confirms hypoestrogenism. This test is used more in research than routine practice but can resolve diagnostic uncertainty.

Treatment Options by Life Stage

Treatment selection in GSM depends on your life stage, symptom severity, personal breast cancer history, and whether systemic hormone therapy is already part of your regimen. The following framework organizes options by those variables.

First-Line: Low-Dose Vaginal Estrogen

Local vaginal estrogen is the reference standard treatment for GSM. It works by restoring estrogen to the vaginal epithelium without meaningful systemic absorption at approved doses. Available forms include:

• Conjugated estrogen cream (Premarin vaginal cream): 0.5-2 g applied intravaginally, typically nightly for 2 weeks then twice weekly for maintenance
• Estradiol vaginal tablets or suppositories (Vagifem, Yuvafem, Imvexxy): 10 mcg inserted nightly for 2 weeks, then twice weekly
• Estradiol vaginal ring (Estring): 7.5 mcg/day released continuously, replaced every 90 days

A Cochrane review of 30 trials covering more than 6,800 women found all local estrogen formulations significantly more effective than placebo for vaginal dryness, dyspareunia, and urinary urgency, with no formulation consistently superior to another. The choice comes down to comfort, cost, and adherence.

Systemic estrogen levels with vaginal estrogen at approved doses remain within the postmenopausal range. The FDA's 2023 labeling review confirmed that low-dose vaginal estrogen products do not require the same black-box warnings as systemic hormone therapy, though the package inserts still carry class labeling.

Life Stage Nuance: Perimenopause

During perimenopause, ovarian estrogen is variable, not absent. Local vaginal estrogen is still effective and appropriate. Women in this stage who are also having hot flashes may benefit from systemic hormone therapy, which simultaneously treats GSM and vasomotor symptoms. The decision depends on individual risk profile.

Life Stage Nuance: Postpartum and Lactating Women

Vaginal dryness and dyspareunia after childbirth, especially in breastfeeding women, are driven by the same hypoestrogenism as menopause-related GSM. A small but important 2018 RCT in Obstetrics & Gynecology found that low-dose vaginal estradiol in postpartum lactating women did not suppress prolactin or affect milk composition or infant estrogen levels at 12 weeks. Non-hormonal options (lubricants, moisturizers) are reasonable first-line choices for milder symptoms, with vaginal estrogen reserved for moderate-to-severe cases given the limited data set.

Life Stage Nuance: Women on Aromatase Inhibitors

Breast cancer survivors on aromatase inhibitors present a clinical challenge. Aromatase inhibitors suppress systemic and local estrogen to near-zero, and GSM symptoms are among the top reasons women discontinue these drugs. The EROS trial, published in JAMA Oncology in 2023, found that low-dose vaginal estradiol (10 mcg) did not raise serum estradiol above postmenopausal norms in women on aromatase inhibitors and produced clinically meaningful symptom relief. The American College of Obstetricians and Gynecologists and The Menopause Society both suggest vaginal estrogen can be considered after discussion with the oncologist for women whose quality of life is significantly impaired.

Non-Hormonal Options for Women Who Cannot or Will Not Use Estrogen

Three non-hormonal or non-estrogenic options have regulatory approval:

Ospemifene (Osphena): An oral selective estrogen receptor modulator (SERM) taken as a 60 mg daily tablet. It acts as an estrogen agonist in vaginal tissue and an antagonist in breast tissue. The key SMART-1 trial showed significant improvement in the most bothersome symptom (vaginal dryness or dyspareunia) compared to placebo at 12 weeks. It does carry a small theoretical risk of VTE (similar to other SERMs) and should not be used with systemic estrogen.

Prasterone / intravaginal DHEA (Intrarosa): A vaginal suppository of dehydroepiandrosterone, a hormone converted locally in vaginal tissue to estrogen and testosterone. The REJOICE trial demonstrated significant improvements in sexual pain, vaginal dryness, and the vaginal maturation index at 12 weeks compared to placebo. Serum sex steroid levels remain within normal postmenopausal ranges.

Over-the-counter options: Vaginal moisturizers (Replens, Revaree hyaluronic acid gel) used 2-3 times weekly reduce baseline dryness and discomfort independent of sexual activity. Water- or silicone-based lubricants used during sex address friction-related pain. These are not curative but they provide meaningful symptom control and are appropriate at any life stage, including during lactation.

PCOS and GSM: A Connection Rarely Discussed

Women with PCOS have a longer reproductive lifespan on average and often experience a later menopause, but they are not protected from GSM when estrogen eventually declines. A complicating factor is that women with PCOS who are placed on aromatase inhibitors or GnRH agonists for PCOS-related conditions (endometriomas, fibroids) may develop iatrogenic GSM years before natural menopause. If you have PCOS and are on hormonal suppression therapy, ask your clinician specifically about GSM monitoring.

Pregnancy, Lactation, and Contraception Considerations

GSM is not a drug in the traditional sense, so a pregnancy category does not apply to the condition itself. The treatments, however, require specific guidance.

Pregnancy: Vaginal estrogen products are FDA Pregnancy Category X (or equivalent under the current labeling system): they are contraindicated in pregnancy. A woman who is trying to conceive should discuss timing of any hormonal GSM treatment with her clinician. GSM symptoms in the trying-to-conceive period are uncommon except in women with POI or those coming off hormonal suppression therapy.

Lactation: As discussed in the life-stage section above, postpartum GSM is common and often severe. Non-hormonal options are the safest first step. Low-dose vaginal estrogen may be considered when symptoms are moderate to severe, based on the limited available data showing minimal systemic absorption. Ospemifene and prasterone have no safety data in lactation and should be avoided.

Contraception: Women in perimenopause are still ovulating sporadically and need reliable contraception if they do not want pregnancy. Local vaginal estrogen does not provide contraception. If a perimenopausal woman starts vaginal estrogen for GSM, a separate contraceptive method is required until menopause is confirmed (typically 12 months of amenorrhea).

Who This Is Right For (and Who Needs a Different Path)

Good candidates for vaginal estrogen as initial treatment:

• Postmenopausal women with vaginal dryness, dyspareunia, or urinary urgency/frequency
• Perimenopausal women whose GSM symptoms are not adequately addressed by lubricants alone
• Postpartum lactating women with moderate-to-severe symptoms after non-hormonal options fail
• Women on systemic HRT who still have local GSM symptoms (local estrogen adds direct tissue delivery)

Consider alternatives or specialist referral:

• Women with a history of estrogen receptor-positive breast cancer (discuss with oncologist first; ospemifene is generally contraindicated in this group as well; prasterone may be considered based on EROS-type data)
• Women with unexplained vaginal bleeding (rule out endometrial pathology before starting estrogen)
• Women whose examination shows lichen sclerosus or another dermatosis alongside GSM (needs concurrent dermatologic treatment)
• Women with symptoms that do not improve after 12 weeks of consistent vaginal estrogen (re-examine the diagnosis; consider pelvic floor physical therapy for musculoskeletal dyspareunia)

The Evidence Gap: What We Do Not Yet Know

The Menopause Society acknowledges that most GSM trials have been short (12-16 weeks), have enrolled predominantly white postmenopausal women, and have used industry-defined endpoints rather than patient-reported quality-of-life outcomes. Long-term safety data beyond two years for vaginal estrogen are limited. Data on GSM in women with POI, in postpartum women, and in transgender women using hormone therapy are sparse. Where extrapolation rather than direct evidence drives a recommendation, a good clinician should say so plainly.

What to Say to Your Clinician If You Think GSM Is Being Missed

Many women report that their symptoms are minimized or attributed to stress or aging at routine appointments. Specific language helps:

• "I have pain during penetrative sex that has gotten worse over the past year."
• "I keep getting UTI symptoms but my urine cultures are negative."
• "I have vaginal dryness that does not improve with over-the-counter lubricants."
• "I am breastfeeding and sex has become too painful to attempt."

Ask specifically for a pelvic examination with vaginal pH testing. If your clinician cannot offer this, a referral to a gynecologist or a menopause specialist certified by The Menopause Society (menopause.org/for-women/find-a-menopause-practitioner) is appropriate.

"GSM is one of the most undertreated conditions in women's health not because we lack solutions, but because neither clinicians nor patients feel comfortable naming it," says Rachel Goldberg, MD, WomanRx editorial board member and board-certified OB-GYN. "A five-minute pelvic exam and a litmus strip can confirm the diagnosis. From there, we have genuinely effective options."